Libra Infusions Ltd.
DDSE:LIBRAINFU502.30
BDT
-4.40
(-0.87%)
ISIN
BD0471LBINF8
Return %
Stock
S&P 500
1Y
-27.35
14.20
3Y
-44.03
81.12
5Y
-3.21
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Roushon Alam
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Jul 9, 1994
- Website
- libragroupbd.com
- Similar Companies
- Business
- Libra Infusions Limited is a Bangladesh-based pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of intravenous (I.V.) fluids, large volume parenterals (LVPs), and specialized therapeutic injectable solutions. The company operates within the pharmaceuticals and life sciences industry, serving hospitals, diagnostic centers, medical institutions, retail pharmacies, and government healthcare programs throughout Bangladesh and selected export territories. The company's product portfolio is systematically categorized into rehydration solutions, electrolyte replacement fluids, intravenous nutrients, and therapeutic injectables; its electrolyte and rehydration offerings include NORMASOL (0.9% sodium chloride/normal saline); DIASOL (cholera saline for acute diarrhoeal diseases and severe electrolyte loss); HARTSOL and HARTSOL PLUS (Hartmann's solution/compound sodium lactate for metabolic acidosis and fluid restoration); BABY SALINE (pediatric electrolyte replacement); and ADS-10 (sodium chloride and dextrose injection); its intravenous nutritional and carbohydrate solutions include LIBOTT and its variants (LIBOTT-5, LIBOTT-10, LIBOTT-25, LIBOTT-S, LIBOTT-S JR, and LIBOTT-M, containing dextrose aqueous and dextrose with sodium chloride formulations across varying concentrations); its anti-infective and therapeutic injectable range comprises LIBRAZOL (metronidazole IV infusion for anaerobic infections); LIBRACIN and LIBRACIN-400 (ciprofloxacin lactate IV infusion for broad-spectrum antibacterial therapy); and LIBRET (ranitidine hydrochloride injection for acid-peptic disorders); alongside concentrated peritoneal and hemodialysis fluid formulations engineered for clinical renal care. Products are manufactured in sterile, non-toxic medical-grade plastic containers in compliance with ISO 9001 quality management protocols. Founded in February 1976 and commencing commercial operations in 1985 through an initial technical collaboration with Vifor S.A. of Switzerland, Libra Infusions Limited is headquartered in Dhaka, Bangladesh, operating its primary manufacturing facility in the Mirpur Industrial Estate, Dhaka. In recent corporate and operational developments, Libra Infusions Limited has advanced strategic capital projects and operational enhancements. The company invested in specialized automated machinery imported from China to launch a dedicated, large-scale dialysis fluid production plant aimed at fulfilling rising domestic renal care demand and penetrating export markets. Following a temporary facility shutdown for maintenance and technical overhauls in mid-2025, the company restored full manufacturing operations at its Mirpur complex to normalize supply volumes. Additionally, the company reorganized its key management functions, appointing a new Company Secretary in late 2025, while undertaking ongoing capital structure and operational adjustments to align with regulatory paid-up capital directives from the Bangladesh Securities and Exchange Commission (BSEC).